IBDEI1ZW ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,33854,1,4,0)
 ;;=4^C83.70
 ;;^UTILITY(U,$J,358.3,33854,2)
 ;;=^5001591
 ;;^UTILITY(U,$J,358.3,33855,0)
 ;;=D09.0^^131^1680^39
 ;;^UTILITY(U,$J,358.3,33855,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33855,1,3,0)
 ;;=3^Carcinoma in Situ of Bladder
 ;;^UTILITY(U,$J,358.3,33855,1,4,0)
 ;;=4^D09.0
 ;;^UTILITY(U,$J,358.3,33855,2)
 ;;=^267742
 ;;^UTILITY(U,$J,358.3,33856,0)
 ;;=D06.9^^131^1680^40
 ;;^UTILITY(U,$J,358.3,33856,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33856,1,3,0)
 ;;=3^Carcinoma in Situ of Cervix
 ;;^UTILITY(U,$J,358.3,33856,1,4,0)
 ;;=4^D06.9
 ;;^UTILITY(U,$J,358.3,33856,2)
 ;;=^5001941
 ;;^UTILITY(U,$J,358.3,33857,0)
 ;;=D06.0^^131^1680^42
 ;;^UTILITY(U,$J,358.3,33857,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33857,1,3,0)
 ;;=3^Carcinoma in Situ of Endocervix
 ;;^UTILITY(U,$J,358.3,33857,1,4,0)
 ;;=4^D06.0
 ;;^UTILITY(U,$J,358.3,33857,2)
 ;;=^5001938
 ;;^UTILITY(U,$J,358.3,33858,0)
 ;;=D06.1^^131^1680^43
 ;;^UTILITY(U,$J,358.3,33858,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33858,1,3,0)
 ;;=3^Carcinoma in Situ of Exocervix
 ;;^UTILITY(U,$J,358.3,33858,1,4,0)
 ;;=4^D06.1
 ;;^UTILITY(U,$J,358.3,33858,2)
 ;;=^5001939
 ;;^UTILITY(U,$J,358.3,33859,0)
 ;;=D06.7^^131^1680^41
 ;;^UTILITY(U,$J,358.3,33859,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33859,1,3,0)
 ;;=3^Carcinoma in Situ of Cervix,Other Parts
 ;;^UTILITY(U,$J,358.3,33859,1,4,0)
 ;;=4^D06.7
 ;;^UTILITY(U,$J,358.3,33859,2)
 ;;=^5001940
 ;;^UTILITY(U,$J,358.3,33860,0)
 ;;=D04.9^^131^1680^44
 ;;^UTILITY(U,$J,358.3,33860,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33860,1,3,0)
 ;;=3^Carcinoma in Situ of Skin
 ;;^UTILITY(U,$J,358.3,33860,1,4,0)
 ;;=4^D04.9
 ;;^UTILITY(U,$J,358.3,33860,2)
 ;;=^5001925
 ;;^UTILITY(U,$J,358.3,33861,0)
 ;;=C91.11^^131^1680^47
 ;;^UTILITY(U,$J,358.3,33861,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33861,1,3,0)
 ;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,In Remission
 ;;^UTILITY(U,$J,358.3,33861,1,4,0)
 ;;=4^C91.11
 ;;^UTILITY(U,$J,358.3,33861,2)
 ;;=^5001766
 ;;^UTILITY(U,$J,358.3,33862,0)
 ;;=C91.10^^131^1680^48
 ;;^UTILITY(U,$J,358.3,33862,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33862,1,3,0)
 ;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,Not in Remission
 ;;^UTILITY(U,$J,358.3,33862,1,4,0)
 ;;=4^C91.10
 ;;^UTILITY(U,$J,358.3,33862,2)
 ;;=^5001765
 ;;^UTILITY(U,$J,358.3,33863,0)
 ;;=C92.11^^131^1680^49
 ;;^UTILITY(U,$J,358.3,33863,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33863,1,3,0)
 ;;=3^Chronic Myeloid Leukemia,BCR/ABL-Positive,In Remission
 ;;^UTILITY(U,$J,358.3,33863,1,4,0)
 ;;=4^C92.11
 ;;^UTILITY(U,$J,358.3,33863,2)
 ;;=^5001793
 ;;^UTILITY(U,$J,358.3,33864,0)
 ;;=C92.10^^131^1680^50
 ;;^UTILITY(U,$J,358.3,33864,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33864,1,3,0)
 ;;=3^Chronic Myeloid Leukemia,BCR/ABL-Positive,Not in Remission
 ;;^UTILITY(U,$J,358.3,33864,1,4,0)
 ;;=4^C92.10
 ;;^UTILITY(U,$J,358.3,33864,2)
 ;;=^5001792
 ;;^UTILITY(U,$J,358.3,33865,0)
 ;;=D47.1^^131^1680^51
 ;;^UTILITY(U,$J,358.3,33865,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33865,1,3,0)
 ;;=3^Chronic Myeloproliferative Disease
 ;;^UTILITY(U,$J,358.3,33865,1,4,0)
 ;;=4^D47.1
 ;;^UTILITY(U,$J,358.3,33865,2)
 ;;=^5002256
 ;;^UTILITY(U,$J,358.3,33866,0)
 ;;=C82.69^^131^1680^52
 ;;^UTILITY(U,$J,358.3,33866,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33866,1,3,0)
 ;;=3^Cutaneous Follicle Center Lymphoma,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,33866,1,4,0)
 ;;=4^C82.69
 ;;^UTILITY(U,$J,358.3,33866,2)
 ;;=^5001530
 ;;^UTILITY(U,$J,358.3,33867,0)
 ;;=C82.60^^131^1680^53
